Glycemic management in patients with immune-related diabetes mellitus: A scoping review
Immune checkpoint inhibitors therapy in cancer patients may induce immune-related diabetes mellitus through islet β-cell destruction, necessitating systematic glycemic management. This scoping review aims to identify and synthesize evidence on glycemic management strategies for immune-related diabet...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121251358313 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Immune checkpoint inhibitors therapy in cancer patients may induce immune-related diabetes mellitus through islet β-cell destruction, necessitating systematic glycemic management. This scoping review aims to identify and synthesize evidence on glycemic management strategies for immune-related diabetes mellitus. Guided by Arksey and O’Malley’s five-stage scoping review framework, we strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. A systematic search was conducted across guideline repositories, academic databases, and professional oncology/endocrinology association websites. The search period spanned from database inception to June 30, 2024. Of 5085 initially identified records, 9 studies met inclusion criteria. Evidence was synthesized into five key domains: (1) risk assessment and early detection, (2) therapeutic interventions and monitoring, (3) patient education, (4) glycemic target optimization, and (5) multidisciplinary care coordination. This review consolidates evidence-based best practices for immune-related diabetes mellitus management derived from rigorous methodology. Clinicians should tailor these strategies to individual patient profiles to optimize outcomes while mitigating treatment disruptions. |
|---|---|
| ISSN: | 2050-3121 |